secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000950170-25-059479
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints Mark Hensley as COO effective April 28, 2025
------------------------------------------------------------------------

- Annual base salary of $553,000; target cash bonus of $276,500 (50% of base), prorated for 2025.
- Inducement awards: option for 500K shares, 500K RSUs, and performance option for up to 900K shares.
- Vesting: option and RSUs vest over 4 years; performance option vests upon stock price goals.
- Hensley previously served as CEO of Veloxis Pharmaceuticals from 2021 to 2024.
- Awards granted outside 2007 Plan as material inducement under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017025059479/0000950170-25-059479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017025059479/hrtx-20250428.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-059479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer